Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer

Gunter von Minckwitz, MD
Published: Sunday, Mar 13, 2016



Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

More research needs to be conducted to understand the optimal use of neoadjuvant therapy, von Minckwitz explains. Biomarkers have been developed in order to determine response to treatment, as well as serve as predictive markers of pathologic complete response rates and poor predictive markers of outcomes.

Additionally, researchers can develop findings from a correlative marker in the neoadjuvant setting that can be then confirmed to the adjuvant setting.

<<< View more from the 33rd Annual Miami Breast Cancer Conference



Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

More research needs to be conducted to understand the optimal use of neoadjuvant therapy, von Minckwitz explains. Biomarkers have been developed in order to determine response to treatment, as well as serve as predictive markers of pathologic complete response rates and poor predictive markers of outcomes.

Additionally, researchers can develop findings from a correlative marker in the neoadjuvant setting that can be then confirmed to the adjuvant setting.

<<< View more from the 33rd Annual Miami Breast Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x